For the treatment of thrombocytopenia in adult patients with chronic liver disease before a scheduled procedure

DOPTELET is the first oral thrombopoietin (TPO) receptor agonist approved for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure

DOPTELET® (avatrombopag) tablets

About DOPTELET

In 2 robust Phase III studies

  • Significantly more patients taking DOPTELET reached a platelet count of 50,000/µL compared to placebo (p<.0001)*1
  • Significantly reduced the need for platelet transfusion or any rescue procedure for bleeding compared to placebo (p<.0001)†1
  • Safety profile was similar to placebo1

*On procedure day, 10 to 13 days after starting DOPTELET 40 mg or DOPTELET 60 mg once daily for 5 days, compared to placebo (p<.0001; N=435).1

From randomization of DOPTELET 40 mg or DOPTELET 60 mg once daily for 5 days up to 7 days after a procedure, compared to placebo (p<.0001; N=435).1

Patients take DOPTELET for 5 days in a row

DOPTELET Increased Patients' Platelet Count
With 5-Day Oral Dosing

  • As a TPO receptor agonist, DOPTELET stimulates megakaryocytes to increase platelet production1
  • DOPTELET does not block native TPO, allowing for an additive effect1
  • Onset of effect is seen in 3 to 5 days with peak platelet levels achieved after 10 to 13 days1

View the DOPTELET Mechanism of Action

Reference:

1.    DOPTELET [package insert]. Durham, NC: Dova Pharmaceuticals, Inc.; 2018.